These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 31268205
21. Tanshinone IIA alleviates blast-induced inflammation, oxidative stress and apoptosis in mice partly by inhibiting the PI3K/Akt/FoxO1 signaling pathway. Liu Y, Tong C, Tang Y, Cong P, Liu Y, Shi X, Shi L, Zhao Y, Jin H, Li J, Hou M. Free Radic Biol Med; 2020 May 20; 152():52-60. PubMed ID: 32131025 [Abstract] [Full Text] [Related]
22. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. Li B, Ding CM, Li YX, Peng JC, Geng N, Qin WW. Oncol Rep; 2018 Mar 20; 39(3):1227-1234. PubMed ID: 29344640 [Abstract] [Full Text] [Related]
23. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Zhao L, Zhang J, Fan Y, Li Y. Med Sci Monit; 2019 Oct 21; 25():7864-7871. PubMed ID: 31631173 [Abstract] [Full Text] [Related]
29. Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway. Liao XZ, Tao LT, Liu JH, Gu YY, Xie J, Chen Y, Lin MG, Liu TL, Wang DM, Guo HY, Mo SL. Cancer Cell Int; 2017 Oct 21; 17():124. PubMed ID: 29299027 [Abstract] [Full Text] [Related]
30. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Wu DM, Zhang T, Liu YB, Deng SH, Han R, Liu T, Li J, Xu Y. Cell Death Dis; 2019 Apr 25; 10(5):349. PubMed ID: 31024010 [Abstract] [Full Text] [Related]
31. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. Wang M, Liu ZM, Li XC, Yao YT, Yin ZX. J Chemother; 2013 Jun 25; 25(3):162-9. PubMed ID: 23783141 [Abstract] [Full Text] [Related]
32. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer]. Zhang Y, Lu H, Xu G. Zhongguo Fei Ai Za Zhi; 2014 Aug 20; 17(8):635-42. PubMed ID: 25130971 [Abstract] [Full Text] [Related]
38. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. So KS, Rho JK, Choi YJ, Kim SY, Choi CM, Chun YJ, Lee JC. Anticancer Res; 2015 Mar 20; 35(3):1537-42. PubMed ID: 25750308 [Abstract] [Full Text] [Related]
39. Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Liao X, Gao Y, Liu J, Tao L, Xie J, Gu Y, Liu T, Wang D, Xie D, Mo S. Front Oncol; 2020 Mar 20; 10():1756. PubMed ID: 33014864 [Abstract] [Full Text] [Related]
40. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, Liu T, Wang D, Ge H, Mo SL. Acta Pharm Sin B; 2015 Nov 20; 5(6):554-63. PubMed ID: 26713270 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]